Following Clinuvel's landmark filing of a marketing authorisation application for the drug SCENESSE® (afamelanotide) with the European Medicines Agency, CEO Dr Philippe Wolgen discusses the challenges to date and what may lie ahead for Clinuvel.

Loading more stuff…

Hmm…it looks like things are taking a while to load. Try again?

Loading videos…